Skip to main content

Table 1 Dose and mode of administration of the study drugsa

From: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Study drugDose and mode of administration
Capecitabine1000 mg/m2 per os twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a 7-day resting period (i.e. off-treatment)
Bevacizumab15 mg/kg intravenously once every 3 weeks (i.e. 5 mg/kg/week dose equivalent)
Everolimus10 mg per os once daily of each 21-day cycle
Exemestane25 mg per os once daily of each 21-day cycle
  1. aDose and mode of administration of the study drugs were in accordance with current SmPC of respective study drug. Study drugs were available upon prescription by respective treating physician. A cycle was defined as 21 days of study treatment